Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/11/9120 |
| _version_ | 1797597508851990528 |
|---|---|
| author | Daniel Åberg Gustaf Gadd Katarina Jood Petra Redfors Tara M. Stanne Jörgen Isgaard Kaj Blennow Henrik Zetterberg Christina Jern N. David Åberg Johan Svensson |
| author_facet | Daniel Åberg Gustaf Gadd Katarina Jood Petra Redfors Tara M. Stanne Jörgen Isgaard Kaj Blennow Henrik Zetterberg Christina Jern N. David Åberg Johan Svensson |
| author_sort | Daniel Åberg |
| collection | DOAJ |
| description | Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (<i>p</i> < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality. |
| first_indexed | 2024-03-11T03:07:03Z |
| format | Article |
| id | doaj.art-e2fa32b22534444ca659a73e336312b1 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T03:07:03Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e2fa32b22534444ca659a73e336312b12023-11-18T07:54:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-012411912010.3390/ijms24119120Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational StudyDaniel Åberg0Gustaf Gadd1Katarina Jood2Petra Redfors3Tara M. Stanne4Jörgen Isgaard5Kaj Blennow6Henrik Zetterberg7Christina Jern8N. David Åberg9Johan Svensson10Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45 Gothenburg, SwedenDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45 Gothenburg, SwedenDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, SwedenDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, SwedenDepartment of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, SwedenDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45 Gothenburg, SwedenRegion Västra Götaland, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80 Mölndal, SwedenRegion Västra Götaland, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80 Mölndal, SwedenDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, SwedenDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45 Gothenburg, SwedenDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45 Gothenburg, SwedenInsulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (<i>p</i> < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality.https://www.mdpi.com/1422-0067/24/11/9120all-cause mortalitybody mass index (BMI)insulin-like growth factor-binding protein-1 (IGFBP-1)ischemic strokemodified Rankin Scale (mRS)mortality |
| spellingShingle | Daniel Åberg Gustaf Gadd Katarina Jood Petra Redfors Tara M. Stanne Jörgen Isgaard Kaj Blennow Henrik Zetterberg Christina Jern N. David Åberg Johan Svensson Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study International Journal of Molecular Sciences all-cause mortality body mass index (BMI) insulin-like growth factor-binding protein-1 (IGFBP-1) ischemic stroke modified Rankin Scale (mRS) mortality |
| title | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
| title_full | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
| title_fullStr | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
| title_full_unstemmed | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
| title_short | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
| title_sort | serum igfbp 1 concentration as a predictor of outcome after ischemic stroke a prospective observational study |
| topic | all-cause mortality body mass index (BMI) insulin-like growth factor-binding protein-1 (IGFBP-1) ischemic stroke modified Rankin Scale (mRS) mortality |
| url | https://www.mdpi.com/1422-0067/24/11/9120 |
| work_keys_str_mv | AT danielaberg serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT gustafgadd serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT katarinajood serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT petraredfors serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT taramstanne serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT jorgenisgaard serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT kajblennow serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT henrikzetterberg serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT christinajern serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT ndavidaberg serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT johansvensson serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy |